Research for treatments, prevention and a cure
DEBUG INFO [ON]
Page template: single-clinical-trials.php
Search terms : 

Clinical Trials

  • Clinical Studies

Prevention and Vulnerable Populations (PVP)


CTN 268: ANRS IPERGAY trial

Study Results
 

Print Friendly, PDF & Email

About the study

This study tested to see if the pill TDF/FTC (Truvada®) can offer protection against HIV infection if taken on an intermittent or ‘on demand’ basis as pre-exposure prophylaxis (PrEP). The medication has been shown to have some effectiveness as a tool for preventing HIV when taken on a daily basis, but the effectiveness of daily PrEP is very much dependent on adherence to treatment. When compared to daily use, on-demand PrEP could have significant benefits such as easier adherence that would make the treatment more effective, as well as lower costs.

About the disease/condition

Risk of HIV infection continues to be a serious health concern. In Quebec, the rate of HIV infection rose between 1997 and 2002. Study researchers have noted that in 2009 men who have sex with men accounted for the highest population with new HIV diagnoses in Quebec. Current prevention strategies such as the use of condoms have been shown to be effective but also limited in a context of at-risk sexual behaviour. Study researchers seek to identify an additional approach to the prevention of HIV infection that can work with current measures such as the use of condoms.

About the approach/intervention

Adult men who have sex with men, who are HIV-negative but who are exposed by their sexual relations to the risk of HIV infection, were recruited. The study was double-blind so neither participants nor researchers knew who was receiving the study drug or a placebo. Community representatives were directly involved in the implementation of the study and were consulted at all stages of the project.

Participants were randomly selected to either join the study drug arm or the placebo arm of the study. In addition to the placebo controlled study drug, all participants were asked to schedule regular visits to a clinic and be offered a complete prevention package to reduce risk (individual support, counselling, screening for HIV and sexually transmitted infections, condoms, lube, and vaccinations for hepatitis A and B).

This study was sponsored by the French National Agency for AIDS Research (ANRS) and was conducted in France and Quebec. In Canada, the study recruited 53 men without HIV infection into the study, the rest of the 400 participants were enrolled in France. Participants, who were randomized to receive the drug, took two pills in the 24-hour period before anticipated sexual intercourse and two separate single-pill doses in the two days following sex.

Results

After a median follow-up of 9.3 months, there was a reduction of 86 percent in the incidence of HIV with on demand PrEP. Sixteen participants acquired HIV-infection after enrolment, 14 in the placebo arm and 2 in the Truvada arm. Participants used a median of 15 pills/month. Adverse responses to Truvada were minimal, the most common complaints being gastrointestinal and kidney issues. Overall, the researchers found that on demand PrEP with oral Truvada is highly effective to reduce the incidence of HIV-infection in high-risk men who have sex with men and has a good safety profile. Further CTN-supported analysis showed that this ‘on demand’ PrEP strategy ranges from cost saving to largely cost-effective. The government of Canada approved the use of Truvada as daily PrEP in February of 2016.

During a presentation at the AIDS 2016 Conference in Durban, South Africa, the results of the long-term follow-up portion of the study were presented. Participants in the long-term arm of the IPERGAY trial were followed for a median length of 11.7 months. The long-term use of Truvada as ‘on demand’ PrEP was found to be as effective at preventing HIV transmission as in the short-term study. The study found that, although condom use declined slightly, it did not have an effect on the ability of the drug to prevent HIV transmission rates. Only one participant (of 362), who had stopped taking PrEP as recommended, acquired HIV during the course of the study

Publications

Durand-Zaleski I, Mutuon P, Charreau I, Tremblay CL, Rojas D, Pialoux G, Chidiac C, Capitant C, Spire B, Cotte L, Chas J, Meyer L. Costs and benefits of on-demand HIV pre-exposure prophylaxis in men who have sex with men analysis of the ANRS IPERGAY study with a one-year follow-up. AIDS. 2017 Oct 12 [epub ahead of print].

Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay CL, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, Cheret A, Timsit J, Girard G, Lorente N, Préau M, Rooney JF, Wainberg MA, Thompson D, Rozenbaum W, Doré V, Marchand L, Simon MC, Etien N, Aboulker JP, Meyer L, Delfraissy JF. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015 Dec 3;373(23):2237–46.

Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, Tremblay CL, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017 Jul 23 [epub ahead of print].

Ouellet E, Durand M, Guertin JR, Lelorier J, Tremblay CL. Cost effectiveness of “on demand” HIV pre-exposure prophylaxis for non-injection drug-using men who have sex with men in Canada. Can J Infect Dis Med Microbiol. 2015 Jan;26(1):23–9.

Sagaon-Teyssier L, Suzan-Monti M, Demoulin B, Capitant C, Lorente N, Préau M, Mora M, Rojas Castro D, Chidiac C, Chas J, Meyer L, Molina JM, Spire B; ANRS IPERGAY Study Group. Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial. AIDS Care. 2016;28(S1):48-55.

Latest News

Why do we need PrEP Guidelines? Ask an expert. VIDEO

| Uncategorized | No Comments

Despite efforts to reduce new incidences of HIV like condom campaigns, needle exchanges, and treatment as prevention, the actual number…

Call for Nominations: Community Advisory Committee (CAC) 2018

| Uncategorized | No Comments

The CIHR Canadian HIV Trials Network (CTN/Network) is an innovative partnership funded by the Canadian Institutes of Health Research to…

Guest Blog: Dr. Nadine Kronfli on HCV treatment in Canadian prisons

| Hepatitis C | No Comments

Persons in custody in Canadian prisons have a 25-fold higher rate of hepatitis C (HCV) infection than the general population….

Guest Blog: CTN Postdoc Dr. Malika Sharma

| Uncategorized | No Comments

CTN Postdoctoral Fellow Dr. Malika Sharma writes about the current state of PrEP in Canada and how CTN 303 looks to change the way these HIV prevention drugs are delivered.

Research for treatments, prevention and a cure